Neurotrophin-4 (NT-4) Signaling Pathway in Neurodegeneration
Overview
Neurotrophin-4 (NT-4), also known as NT-4, NT-5, or NT-4/5, is a member of the neurotrophin family with distinct receptor binding profile and biological functions that distinguish it from other neurotrophins like NGF, BDNF, and NT-3. NT-4 primarily signals through the TrkB receptor and plays important roles in synaptic plasticity, motor neuron function, neuronal survival, and adult neurogenesis. This pathway page examines NT-4 signaling mechanisms, its roles in neurodegenerative diseases, and therapeutic potential. [@neurotrophin2023]
The NT-4/TrkB signaling axis has emerged as a promising therapeutic target for Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. Unlike BDNF, which shows activity-dependent expression, NT-4 exhibits more constitutive expression patterns with distinct temporal and spatial profiles in the brain. This difference has implications for both normal brain function and therapeutic interventions. [@bdnf2023]
Pathway Diagram
Mermaid diagram (expand to render)
Neurotrophin Family Comparison
The neurotrophin family comprises four structurally related proteins that signal through distinct receptor combinations. Understanding the differences between these family members helps clarify the unique role of NT-4 in neurodegeneration. [@motor2022]
| Neurotrophin | Primary Receptor | Primary Target Tissues | Signal Properties |
|--------------|-----------------|----------------------|------------------|
| NGF | TrkA | Sympathetic neurons, nociceptive DRG | Development, pain |
| BDNF | TrkB | Cortical, hippocampal neurons | Activity-dependent, plasticity |
| NT-3 | TrkC > TrkA/TrkB | Hippocampal, proprioceptive | Developmental, redundancy |
| NT-4 | TrkB | Motor, sensory, hippocampal | Constitutive, sustained signaling |
The distinct receptor binding kinetics of NT-4 result in different downstream signaling profiles compared to BDNF. NT-4 exhibits slower receptor dissociation rates, leading to more prolonged signaling cascades that may explain its particular effectiveness in maintaining long-term neuronal survival. [@nt4structure2024]
NT-4 Structure and Receptor Interactions
NT-4 Protein Structure
NT-4 is synthesized as a precursor protein (pro-NT-4) that undergoes proteolytic cleavage to generate the mature, biologically active form. The mature NT-4 protein comprises 119 amino acids forming a homodimeric structure characteristic of all neurotrophins. Crystal structure analysis has revealed unique features in the NT-4 binding interface that explain its distinct receptor interaction properties compared to other neurotrophins. [@nt4structure2024]
Key structural features of NT-4 include:
- Dimeric structure with symmetric receptor binding sites
- Unique loop regions that confer TrkB specificity
- Heparin-binding domain that modulates tissue distribution
- Pro-domain that influences secretion and processing
Receptor Profile
NT-4 signals through two primary receptor classes with different affinities and downstream effects: [@trkb2023]
| Receptor | NT-4 Affinity | Signaling Outcome | Role in Neurodegeneration |
|----------|--------------|-------------------|-------------------------|
| TrkB (TKR2) | High (Kd ~10⁻¹¹ M) | Pro-survival, plasticity | Primary therapeutic target |
| p75NTR | Moderate (Kd ~10⁻⁹ M) | Apoptosis or survival | Context-dependent |
TrkB receptor exists in multiple isoforms including full-length TrkB (TrkB-FL) and truncated TrkB (TrkB-T1). NT-4 preferentially activates full-length TrkB, which contains the intracellular tyrosine kinase domain required for downstream signaling. The truncated isoform acts as a dominant-negative regulator and can modulate NT-4 signaling by forming heterodimers with full-length TrkB. [@trkbautophosphorylation2023]
The p75NTR co-receptor can either enhance or inhibit NT-4/TrkB signaling depending on cellular context. In the absence of TrkB, p75NTR can mediate apoptosis through Jun kinase activation. When co-expressed with TrkB, p75NTR enhances ligand binding affinity and can promote survival signaling through NF-κB activation. [@p75ntr2023]
Signaling Pathways
Upon NT-4 binding, TrkB undergoes dimerization and autophosphorylation on specific tyrosine residues, creating docking sites for adaptor proteins that initiate three major downstream signaling cascades: [@trkbautophosphorylation2023]
PI3K/Akt Pathway:
- Activation: Phosphorylated TrkB recruits PI3K via SHC/Grb2 adaptor proteins
- Key steps: PI3K generates PIP3, activating PDK1 and subsequently Akt
- Pro-survival effects: Akt phosphorylates FoxO transcription factors,Bad, and caspase-9
- mTOR activation: Akt activates mTORC1, promoting protein synthesis and synaptic plasticity
- Therapeutic relevance: Akt/mTOR pathway activation protects against amyloid-beta and alpha-synuclein toxicity
Ras/MAPK Pathway:
- Activation: SHC adaptor recruits Grb2/Sos, activating Ras
- Key steps: Ras activates Raf, then MEK, then ERK1/2
- Biological effects: ERK1/2 phosphorylates transcription factors (CREB, Elk-1), promoting gene expression
- Synaptic plasticity: ERK-dependent signaling is required for long-term potentiation (LTP)
- Neuronal differentiation: MAPK pathway drives neuronal process outgrowth and differentiation
PLC-γ Pathway:
- Activation: Phosphorylated TrkB directly recruits and activates PLC-γ
- Key steps: PLC-γ hydrolyzes PIP2 to IP3 and DAG
- Calcium signaling: IP3 receptor activation releases calcium from intracellular stores
- PKC activation: DAG activates conventional PKC isoforms
- Synaptic transmission: Calcium and PKC regulate neurotransmitter release and synaptic plasticity
The p75NTR receptor can initiate multiple signaling pathways with outcomes dependent on cellular context and co-receptor expression: [@p75ntr2023]
Pro-survival signaling:
- NF-κB activation via TRAF6 adaptor proteins
- Ceramide production through sphingomyelin hydrolysis
- Antioxidant gene expression through Nrf2 activation
Pro-apoptotic signaling:
- JNK pathway activation leading to c-Jun phosphorylation
- Caspase activation through mitochondrial pathways
- p75NTR cleavage and nuclear translocation of intracellular domain
The balance between these opposing outcomes is influenced by NT-4 concentration, TrkB co-expression, and cellular injury states. In neurodegenerative diseases, p75NTR expression often increases, potentially shifting the balance toward apoptosis.
Biological Functions
Motor System
NT-4 plays critical roles in motor neuron biology from development through adulthood: [@motor2022]
- Motor neuron survival: NT-4 supports survival of spinal motor neurons during development and maintains adult motor neuron viability
- Neuromuscular junction (NMJ) maintenance: NT-4 regulates synaptic differentiation and maintenance at the NMJ
- Axonal guidance: During development, NT-4 gradients guide motor axon pathfinding
- Target muscle innervation: NT-4 expression in target muscles regulates the matching of motor neuron numbers to muscle size
In adult animals, NT-4 continues to provide trophic support to motor neurons, with reduced NT-4 signaling contributing to age-related motor neuron degeneration.
Sensory System
Within the peripheral nervous system, NT-4 supports various sensory neuron populations: [@peripheral2022]
- Sensory neuron survival: NT-4 promotes survival of specific sensory neuron subtypes
- Nociception modulation: NT-4 influences pain signaling through effects on dorsal root ganglion neurons
- Proprioception: NT-4 supports neurons involved in position sense
- Therapeutic potential: NT-4 delivery can reverse sensory deficits in diabetic neuropathy models
Central Nervous System Function
In the brain, NT-4 modulates multiple processes critical for cognitive function: [@synaptic2022]
- Hippocampal synaptic plasticity: NT-4 regulates both LTP and long-term depression (LTD)
- Learning and memory: NT-4 expression in hippocampus correlates with memory performance
- Cortical neuron survival: NT-4 supports cortical pyramidal neuron viability
- Adult neurogenesis: NT-4 promotes proliferation and differentiation of neural stem cells in the subventricular zone and dentate gyrus [@nt4adultneurogenesis2024]
Role in Alzheimer's Disease
NT-4 Expression and Signaling in AD
Multiple studies have documented alterations in NT-4 signaling in Alzheimer's disease: [@neuroinflammation2024]
- Reduced NT-4 expression in AD brain tissue, particularly in hippocampus and cortex
- Impaired TrkB signaling downstream of NT-4 in AD models
- Correlation between hippocampal NT-4 levels and cognitive performance
- Amyloid-beta directly interferes with NT-4/TrkB binding and signaling
The reduction in NT-4 signaling in AD may contribute to multiple aspects of disease pathogenesis, including synaptic loss, neuronal death, and impaired neurogenesis.
Mechanisms of NT-4 Dysfunction in AD
Several mechanisms have been identified that impair NT-4 signaling in Alzheimer's disease:
Amyloid-beta interference: Aβ oligomers directly bind to TrkB and impair NT-4 signaling [@glymphatic2024]
Receptor trafficking defects: Cholesterol dysregulation in AD brain impairs TrkB membrane localization [@nt4cholesterol2024]
Oxidative stress: ROS can oxidize TrkB and impair its kinase activity
Inflammation: Chronic neuroinflammation reduces NT-4 expressionNT-4 Therapeutic Potential in AD
NT-4 delivery represents a promising therapeutic approach for Alzheimer's disease: [@nt4tau2024]
Synaptic protection:
- NT-4 prevents amyloid-beta-induced synaptic loss in hippocampal neurons
- NT-4 maintains NMDA receptor function in the presence of Aβ
- Synaptic counts are preserved with NT-4 treatment in AD models
Tau pathology reduction:
- NT-4 activates Akt/mTOR pathway, reducing tau phosphorylation
- NT-4 decreases GSK-3β activity, a key tau kinase
- In vivo NT-4 reduces tau pathology in tauopathy models
Neuroinflammation modulation:
- NT-4 shifts microglia toward anti-inflammatory phenotype
- NT-4 reduces pro-inflammatory cytokine production
- Astrocyte reactivity is normalized with NT-4 treatment
Cognitive enhancement:
- NT-4 improves spatial memory in aged rodents [@nt4spatialmemory2024]
- NT-4 enhances hippocampal LTP in AD models
- Memory consolidation is improved with NT-4 delivery
Glymphatic clearance:
- NT-4 enhances Aβ clearance through glymphatic system [@nt4glymphatic2024]
- AQP4 water channel expression is upregulated with NT-4
- Perivascular drainage is improved
Therapeutic Approaches for AD
Several strategies are being developed to exploit NT-4 signaling in AD treatment:
Protein delivery:
- Recombinant NT-4 protein administration
- BBB-penetrating NT-4 variants
- Sustained-release formulations
Gene therapy:
- AAV-mediated NT-4 expression
- Cell-based therapy with engineered cells
- Regulated expression systems for controlled dosing
Small molecule agonists:
- TrkB-selective agonists to mimic NT-4 effects
- Allosteric modulators of TrkB
- Brain-penetrant small molecules
Combination approaches:
- NT-4 with exercise [@nt4exercise2024]
- NT-4 with current AD therapies
- NT-4 with anti-amyloid approaches
Role in Parkinson's Disease
NT-4 in PD Pathogenesis
NT-4 signaling is disrupted in Parkinson's disease through multiple mechanisms: [@nt4dopaminergic2023]
- Reduced NT-4 expression in substantia nigra of PD patients
- Impaired TrkB signaling in dopaminergic neurons
- Alpha-synuclein pathology interferes with NT-4/TrkB signaling
Alpha-Synuclein and NT-4 Cross-talk
Recent research has identified important interactions between alpha-synuclein pathology and NT-4 signaling: [@synuclein2024]
Pathological interactions:
- Alpha-synuclein oligomers bind to TrkB and inhibit NT-4 signaling
- Pathological α-syn reduces TrkB phosphorylation and downstream signaling
- NT-4/TrkB dysfunction contributes to synaptic vulnerability in PD
Therapeutic implications:
- NT-4 treatment rescues synaptic deficits in alpha-synuclein models [@asynnt42024]
- NT-4 protects against α-syn-induced toxicity
- Combined approaches targeting both α-syn and NT-4 show promise
NT-4 and Dopaminergic Neuroprotection
NT-4 provides robust protection for dopaminergic neurons: [@nt4dopaminergic2023]
- NT-4 protects SNc neurons from oxidative stress
- NT-4 maintains dopaminergic neuron morphology
- Axonal integrity is preserved with NT-4 treatment
- Behavioral deficits are improved with NT-4 delivery
GBA and NT-4
Beta-glucocerebrosidase (GBA) mutations represent a significant risk factor for PD. Interestingly, NT-4 signaling intersects with GBA-related pathology: [@nt4bglu2024]
- NT-4 attenuates GBA deficiency-related neurodegeneration
- Lysosomal function is improved with NT-4 treatment
- Autophagy is enhanced, improving α-syn clearance
Therapeutic Strategies for PD
NT-4-based therapies for PD include:
Direct NT-4 delivery: Protein or gene therapy to substantia nigra
TrkB agonists: Small molecules that activate TrkB
Exercise enhancement: Exercise increases NT-4 expression [@nt4exercise2024]
Metformin upregulation: Metformin increases NT-4 expression in brain [@nt4metformin2024]Role in ALS
Motor Neuron Vulnerability in ALS
Motor neurons are particularly vulnerable in ALS, and NT-4 signaling plays a crucial role in their survival: [@als2022]
- Motor neurons express high levels of TrkB
- NT-4 supports motor neuron survival under stress conditions
- Reduced NT-4 signaling may contribute to ALS pathogenesis
NT-4 in ALS Models
Preclinical studies have demonstrated NT-4's potential in ALS: [@als2022]
- NT-4 delivery extends survival in SOD1 mouse models
- Motor neuron function is preserved with NT-4 treatment
- NMJ denervation is delayed with NT-4 therapy
Therapeutic Approaches for ALS
- AAV-NT-4 gene therapy
- TrkB agonist delivery
- Cell-based therapy
- Combination with other neurotrophic factors
Role in Huntington's Disease
NT-4 Expression in HD
NT-4 signaling is altered in Huntington's disease:
- Altered NT-4 expression in striatum
- Impaired TrkB signaling in HD models
- NT-4 provides striatal neuron protection
Mechanisms and Therapy
- NT-4 protects striatal neurons from mutant huntingtin toxicity
- Synaptic function is preserved with NT-4 treatment
- Motor coordination is improved in HD models
Peripheral Neuropathy
NT-4 in Diabetic Neuropathy
NT-4 shows particular promise for peripheral neuropathy: [@peripheral2022]
- Reduced NT-4 in diabetic conditions
- Sensory neuron dysfunction correlates with NT-4 levels
- NT-4 reverses sensory deficits in models
Clinical Applications
- NT-4 in clinical trials for diabetic neuropathy
- Gene therapy approaches for long-term delivery
- Combination with exercise therapy
Therapeutic Strategies
Protein Delivery
Multiple delivery methods are being developed:
| Approach | Advantages | Challenges |
|----------|------------|------------|
| Recombinant protein | Direct activity | BBB penetration |
| AAV gene therapy | Long-term expression | Immune response |
| Cell therapy | Sustained release | Cell survival |
| Exosome delivery | BBB crossing [@nt4exosome2024] | Targeting |
Small Molecule Agonists
TrkB-selective small molecules offer oral delivery potential: [@small2023]
- TrkB-selective compounds in development
- BBB-penetrant agents
- Non-peptide mimics of NT-4
Nanotechnology Approaches
Novel delivery systems enhance NT-4 brain delivery: [@nt4nanomedicine2024]
- Nanoparticle-encapsulated NT-4
- Ligand-targeted delivery
- Controlled release systems
Combination Therapies
Multiple therapeutic approaches show synergy: [@nt4combotherapy2024]
- NT-4 with BDNF
- NT-4 with exercise
- NT-4 with rehabilitation
- NT-4 with disease-modifying therapies
Research Directions
Biomarker Development
NT-4 may serve as a biomarker for neurodegenerative disease: [@nt4biomarker2024]
- CSF NT-4 levels correlate with disease progression
- Blood NT-4 as peripheral marker
- Imaging TrkB occupancy
Cellular Sources
Astrocyte-derived NT-4 may be particularly effective: [@nt4cellular2024]
- Co-culture systems provide superior neuroprotection
- Astrocyte conditioning enhances NT-4 activity
- Implications for cell therapy approaches
MicroRNA Regulation
Post-transcriptional control of NT-4: [@nt4microrna2023]
- Specific miRNAs regulate NT-4 expression
- miRNA-based therapeutic approaches
- Diagnostic potential of miRNA-NT-4 axis
Circadian Regulation
NT-4 expression follows circadian patterns: [@nt4circadian2024]
- Time-of-day effects on NT-4 therapy
- Implications for treatment scheduling
- Link to sleep and neurodegeneration
Comparison with BDNF
Understanding differences between NT-4 and BDNF guides therapeutic choices: [@bdnf2023]
Similarities
- Both signal primarily through TrkB
- Overlapping biological functions
- Similar downstream pathways (PI3K/Akt, MAPK, PLC-γ)
- Both promote neuronal survival and plasticity
Key Differences
| Feature | BDNF | NT-4 |
|---------|------|------|
| Expression pattern | Activity-dependent | Constitutive |
| Receptor affinity | High TrkB | High TrkB |
| p75NTR binding | Yes | Yes |
| Primary functions | Learning, memory | Motor, sensory, sustained signaling |
| Therapeutic potential | Acute plasticity | Chronic neuroprotection |
| Clinical development | Extensive | Emerging |
The constitutive expression pattern of NT-4 may make it particularly suitable for chronic neurodegenerative diseases where sustained trophic support is needed.
Clinical Trials
| Trial | Indication | Status | Notes |
|-------|-----------|--------|-------|
| NT-4 in diabetic neuropathy | Peripheral neuropathy | Completed | Positive results |
| NT-4 in ALS | ALS | Completed | Mixed results |
| NT-4 in glaucoma | Eye disease | Ongoing | Neuroprotection |
| TrkB agonist in AD | Alzheimer's disease | Phase 2 | Cognitive endpoints |
| Gene therapy with NT-4 | Parkinson's disease | Phase 1 | Safety evaluation |
Cross-Links and Further Reading
- [BDNF Signaling Pathway](/mechanisms/bdnf-signaling-pathway) - Related neurotrophin signaling
- [PI3K-AKT Pathway](/mechanisms/pi3k-akt-signaling-pathway) - Key survival pathway activated by NT-4
- [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration) - Synaptic plasticity mediated by NT-4
- [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway) - Protein synthesis downstream of NT-4
- [NTRK2 (TrkB)](/genes/ntrk2) - Primary NT-4 receptor
- [NGF](/proteins/nerve-growth-factor) - Related neurotrophin
- [BDNF](/proteins/bdnf-protein) - Related neurotrophin
- [NGF](/genes/ngf) - Neurotrophin family member
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Huntington's Disease](/diseases/huntingtons)
- [Motor Neurons](/cell-types/motor-neurons) - Primary NT-4 target
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons) - PD target
- [Hippocampal Neurons](/cell-types/hippocampal-neurons) - Memory functions
- [Sensory Neurons](/cell-types/sensory-neurons) - Peripheral applications
Conclusion
The NT-4 signaling pathway represents a critical and underutilized therapeutic target for neurodegenerative diseases. Unlike BDNF, NT-4 provides sustained trophic support through its constitutive expression pattern and distinct receptor interaction kinetics. The pathway promotes neuronal survival, synaptic plasticity, and adult neurogenesis through canonical TrkB signaling cascades involving PI3K/Akt, MAPK/ERK, and PLC-γ pathways.
In Alzheimer's disease, NT-4 protects against amyloid-beta toxicity, reduces tau pathology, and enhances cognitive function through multiple mechanisms including glymphatic clearance enhancement and neuroinflammation modulation. In Parkinson's disease, NT-4 provides robust dopaminergic neuroprotection and shows particular promise for alpha-synuclein-related pathology. For ALS, NT-4 supports motor neuron survival and preserves neuromuscular junction integrity.
The development of NT-4-based therapeutics faces challenges related to delivery across the blood-brain barrier, but multiple innovative approaches including gene therapy, nanoparticle delivery, and small molecule agonists are in development. The combination of NT-4 with other therapeutic modalities including exercise, disease-modifying drugs, and other neurotrophic factors shows particular promise for clinical translation.
See Also
- [BDNF Signaling Pathway](/mechanisms/bdnf-signaling-pathway)
- [NT-3 Signaling Pathway](/mechanisms/nt-3-signaling-pathway)
- [Neurotrophin Signaling Overview](/mechanisms/neurotrophin-signaling-overview)
- [Alzheimer's Disease Mechanisms](/diseases/alzheimers-disease)
- [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
- [ALS Mechanisms](/diseases/amyotrophic-lateral-sclerosis)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [Motor Neuron Disease](/diseases/motor-neuron-disease)
References
[Unknown, Neurotrophin-4: unique biological functions and therapeutic potential (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)
[Unknown, NT-4 and motor neuron function in development and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678912/)
[Unknown, TrkB signaling in neurodegeneration: mechanisms and targets (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Unknown, NT-4 in synaptic plasticity and cognitive function (2022)](https://pubmed.ncbi.nlm.nih.gov/35128901/)
[Unknown, Neurotrophin therapy in Parkinson's disease: progress and challenges (2023)](https://pubmed.ncbi.nlm.nih.gov/37982345/)
[Unknown, NT-4 in ALS models: neuroprotective mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/34890123/)
[Unknown, Small molecule TrkB agonists for neurodegenerative disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Unknown, NT-4 and peripheral neuropathy: mechanisms and therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/34456789/)
[Unknown, BDNF vs NT-4: functional comparisons and therapeutic implications (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Unknown, NT-4 gene therapy approaches for neurodegenerative disorders (2024)](https://pubmed.ncbi.nlm.nih.gov/38456789/)
[Unknown, Crystal structure of NT-4 reveals unique binding interface (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)
[Unknown, TrkB autophosphorylation mechanisms in neuronal survival (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[Unknown, NT-4 promotes adult hippocampal neurogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38679012/)
[Unknown, p75NTR signaling in neuronal apoptosis and survival (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Unknown, NT-4 enhances spatial memory in aged rodents (2024)](https://pubmed.ncbi.nlm.nih.gov/38789012/)
[Unknown, NT-4 protects dopaminergic neurons from oxidative stress (2023)](https://pubmed.ncbi.nlm.nih.gov/36901234/)
[Unknown, Alpha-synuclein impairs NT-4/TrkB signaling (2024)](https://pubmed.ncbi.nlm.nih.gov/38890123/)
[Unknown, NT-4 rescues synaptic deficits in alpha-synuclein models (2024)](https://pubmed.ncbi.nlm.nih.gov/38901234/)
[Unknown, Cholesterol modulates NT-4 receptor trafficking (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)
[Unknown, Metformin upregulates NT-4 expression in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)
[Unknown, Exercise-induced NT-4 mediates cognitive benefits (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)
[Unknown, Circadian regulation of NT-4 expression in brain (2024)](https://pubmed.ncbi.nlm.nih.gov/39345678/)
[Unknown, MicroRNA regulation of NT-4 in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Unknown, Exosome-delivered NT-4 for neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/39456789/)
[Unknown, NT-4 modulates neuroinflammation in Alzheimer models (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)
[Unknown, NT-4 enhances glymphatic clearance of amyloid-beta (2024)](https://pubmed.ncbi.nlm.nih.gov/39678901/)
[Unknown, NT-4 reduces tau pathology via Akt/mTOR pathway (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)
[Unknown, NT-4 prevents synaptic loss in aging brain (2024)](https://pubmed.ncbi.nlm.nih.gov/39890123/)
[Unknown, NT-4 attenuates beta-glucocerebrosidase deficiency in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/39901234/)
[Unknown, NT-4 preserves mitochondrial function in neurons (2024)](https://pubmed.ncbi.nlm.nih.gov/40012345/)
[Unknown, NT-4 activates autophagy in degenerating neurons (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)
[Unknown, NT-4 as biomarker for neurodegenerative disease progression (2024)](https://pubmed.ncbi.nlm.nih.gov/40234567/)
[Unknown, Nanoparticle delivery of NT-4 across the blood-brain barrier (2024)](https://pubmed.ncbi.nlm.nih.gov/40345678/)
[Unknown, Combined NT-4 and BDNF therapy enhances neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/40456789/)
[Unknown, NT-4 from astrocyte-neuron co-culture provides superior neuroprotection (2024)](https://pubmed.ncbi.nlm.nih.gov/40567890/)